{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14","value":"1810"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 1/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43","value":"1730"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"130 mg, Cycle 2/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33","value":"2200"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 1/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58","value":"2190"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"185 mg, Cycle 2/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27","value":"3470"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 1/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63","value":"2750"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"240 mg, Cycle 2/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29","value":"4130"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"275 mg, Cycle 1/Day 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23","value":"3620"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"275 mg, Cycle 2/Day 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Cmax is reported for each LY2603618 dose level on Cycle 1 /Day 2 and Cycle 2 /Day 2. The number of pharmacokinetic observations (n) used in the analysis is presented for each dose level and time point.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Cycles 1-2 (21-day cycle):\n\nDay 1: pemetrexed 500 mg/m\\^2 + cisplatin 75 mg/m\\^2\n\nDay 2: LY2603618 130 to 275 mg\n\nAfter 2 cycles, participants may have continued on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion was met.\n\nPemetrexed, cisplatin, and LY2603618 were administered IV over 10 minutes, 1 hour, and 1 hour, respectively.","id":"OG000","title":"Phase 1: Pemetrexed + Cisplatin + LY2603618"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Phase 1 participants who received at least 1 dose of LY2603618 and had samples collected for pharmacokinetic analysis.","reportingStatus":"POSTED","timeFrame":"Cycle 1/Day 2 - immediately prior to end of LY2603618 infusion, and 1, 3, 6, 24, 48, 72, and 144 hours postdose; Cycle 2/Day 2 - predose, immediately prior to end of LY2603618 infusion, and 1, 3, 6, 24, 48, 72, and 144 hours postdose","title":"Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618)","type":"SECONDARY","unitOfMeasure":"ng/mL"}